KR20200143701A - 메탈로-리오티로닌 - Google Patents

메탈로-리오티로닌 Download PDF

Info

Publication number
KR20200143701A
KR20200143701A KR1020207031803A KR20207031803A KR20200143701A KR 20200143701 A KR20200143701 A KR 20200143701A KR 1020207031803 A KR1020207031803 A KR 1020207031803A KR 20207031803 A KR20207031803 A KR 20207031803A KR 20200143701 A KR20200143701 A KR 20200143701A
Authority
KR
South Korea
Prior art keywords
complex
metal
biologically active
active moiety
coordination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207031803A
Other languages
English (en)
Korean (ko)
Inventor
존 디. 프라이스
토마스 피카리엘로
미카엘라 이. 물헤어
Original Assignee
신소닉스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신소닉스, 인코포레이티드 filed Critical 신소닉스, 인코포레이티드
Publication of KR20200143701A publication Critical patent/KR20200143701A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/003—Compounds containing elements of Groups 2 or 12 of the Periodic Table without C-Metal linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
KR1020207031803A 2018-04-04 2019-04-04 메탈로-리오티로닌 Ceased KR20200143701A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652705P 2018-04-04 2018-04-04
US62/652,705 2018-04-04
PCT/US2019/025725 WO2019195513A1 (en) 2018-04-04 2019-04-04 Metallo-liothyronine

Publications (1)

Publication Number Publication Date
KR20200143701A true KR20200143701A (ko) 2020-12-24

Family

ID=68101148

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207031803A Ceased KR20200143701A (ko) 2018-04-04 2019-04-04 메탈로-리오티로닌

Country Status (9)

Country Link
US (2) US11712426B2 (https=)
EP (1) EP3773733B1 (https=)
JP (1) JP7535993B2 (https=)
KR (1) KR20200143701A (https=)
CN (1) CN112218661A (https=)
AU (1) AU2019247217A1 (https=)
BR (1) BR112020020403A8 (https=)
CA (1) CA3096199A1 (https=)
WO (1) WO2019195513A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11712426B2 (en) * 2018-04-04 2023-08-01 Synthonics, Inc. Metallo-liothyronine
JP2022030705A (ja) * 2020-08-07 2022-02-18 日本曹達株式会社 チアベンダゾール含有配位高分子

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298613B1 (it) * 1998-03-10 2000-01-12 Bracco Spa Chelati complessi di manganese ad alta relassivita' in siero
JP2003261683A (ja) * 2002-03-06 2003-09-19 Nof Corp 中性（ベンゼン−１，２，４，５−テトラチオラート）金属錯体ポリマー、その製造方法および用途
US20060141054A1 (en) 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
AU2013205471B2 (en) 2005-10-24 2016-02-11 Synthonics, Inc. Metal coordinated compositions
JP5162758B2 (ja) * 2006-03-02 2013-03-13 大学共同利用機関法人自然科学研究機構 マイクロチャンネルリアクター
EP2536408A1 (en) * 2010-02-16 2012-12-26 Wockhardt Research Centre Efflux pump inhibitors
US10150792B2 (en) * 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
JP6183763B2 (ja) * 2014-05-02 2017-08-23 国立研究開発法人物質・材料研究機構 有機／ヘテロ金属ハイブリットポリマー、その合成方法、有機／ヘテロ金属ハイブリットポリマーの膜、有機／マルチ金属ハイブリットポリマー、その合成方法、及び有機／マルチ金属ハイブリットポリマーの膜
CA2951923A1 (en) * 2014-06-18 2015-12-23 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
JP6838268B2 (ja) * 2015-10-21 2021-03-03 コニカミノルタ株式会社 光変換材料、光変換フィルム、及び発光素子
US11712426B2 (en) * 2018-04-04 2023-08-01 Synthonics, Inc. Metallo-liothyronine

Also Published As

Publication number Publication date
JP7535993B2 (ja) 2024-08-19
EP3773733A4 (en) 2022-05-25
US20230381126A1 (en) 2023-11-30
EP3773733A1 (en) 2021-02-17
US11712426B2 (en) 2023-08-01
CA3096199A1 (en) 2019-10-10
AU2019247217A1 (en) 2020-11-26
EP3773733C0 (en) 2025-11-12
BR112020020403A8 (pt) 2021-04-13
EP3773733B1 (en) 2025-11-12
BR112020020403A2 (pt) 2021-03-23
JP2021521268A (ja) 2021-08-26
CN112218661A (zh) 2021-01-12
US20210046032A1 (en) 2021-02-18
WO2019195513A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
EP3295935B1 (en) Crystallization method and bioavailability
EP2531200B1 (en) Crystallization method and bioavailability
US20230381126A1 (en) Metallo-liothyronine
CA2997378A1 (en) Crystallization method and bioavailability
JP2013542961A (ja) 生理活性物質の性質を調節するビスマス含有化合物
CA2658338A1 (en) Amine dendrimers
AU2014219129A1 (en) Caged platinum nanoclusters for anticancer chemotherapeutics
TWI905111B (zh) 含有對硼苯基丙胺酸之注射液劑
JP2024500539A (ja) バナジウム化合物を用いた疼痛の治療方法
KR790001445B1 (ko) 3-[n'-(3-할로프로필)-n'-메틸아미노]-n,n,n-트리메틸-1-프로판아미늄 할라이드의 제법
HK1171966B (en) Crystallization method and bioavailability
HK1171966A (en) Crystallization method and bioavailability

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201103

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220404

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240416

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250120

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D